Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astrazeneca Plc ADR (NQ: AZN )

78.88 +0.32 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,992,767
Open 78.44
Bid (Size) 78.50 (1)
Ask (Size) 78.88 (4)
Prev. Close 78.56
Today's Range 78.44 - 79.24
52wk Range 60.47 - 80.86
Shares Outstanding N/A
Dividend Yield 1.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits
Explore three top growth-ready healthcare stocks to buy amid rising demand for healthcare services globally. 
Via InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
You won't need much money to start investing in these great stocks. 
Via The Motley Fool

Performance

YTD
+15.32%
+15.32%
1 Month
+0.90%
+0.90%
3 Month
+19.77%
+19.77%
6 Month
+18.62%
+18.62%
1 Year
+9.37%
+9.37%

More News

Read More
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Via MarketBeat
Topics Economy
Exposures Interest Rates
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
Via Benzinga
Exposures Product Safety
3 Best Stocks to Buy From the Fantastic 5
Via InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
Via Benzinga
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
From AstraZeneca
Via Business Wire
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Via Investor's Business Daily
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
Via InvestorPlace
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.